Zomedica Pharmaceuticals Corp Alpha and Beta Analysis
| ZOMDelisted Stock | USD 0.06 0 1.85% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Zomedica Pharmaceuticals Corp. It also helps investors analyze the systematic and unsystematic risks associated with investing in Zomedica Pharmaceuticals over a specified time horizon. Remember, high Zomedica Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Zomedica Pharmaceuticals' market risk premium analysis include:
Beta 3.45 | Alpha (0.69) | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Zomedica |
Zomedica Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Zomedica Pharmaceuticals market risk premium is the additional return an investor will receive from holding Zomedica Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Zomedica Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Zomedica Pharmaceuticals' performance over market.| α | -0.69 | β | 3.45 |
Zomedica Pharmaceuticals Fundamentals Vs Peers
Comparing Zomedica Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Zomedica Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Zomedica Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Zomedica Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Zomedica Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Zomedica Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Zomedica Pharmaceuticals to competition |
| Fundamentals | Zomedica Pharmaceuticals | Peer Average |
| Return On Equity | -0.27 | -0.31 |
| Return On Asset | -0.0978 | -0.14 |
| Profit Margin | (2.33) % | (1.27) % |
| Operating Margin | (1.06) % | (5.51) % |
| Current Valuation | (17.8 M) | 16.62 B |
| Shares Outstanding | 979.95 M | 571.82 M |
| Shares Owned By Insiders | 1.86 % | 10.09 % |
Zomedica Pharmaceuticals Opportunities
Zomedica Pharmaceuticals Return and Market Media
The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Russell Klass of 200000 shares of Zomedica Pharmaceuticals at 0.12 subject to Rule 16b-3 | 02/21/2025 |
2 | Leading Proxy Advisory Firm ISS Recommends Zomedica Shareholders Vote FOR Proposed Reverse Stock Split - ACCESS Newswire | 03/03/2025 |
3 | Earnings call transcript Zomedica Q4 2024 shows revenue growth - Investing.com | 03/13/2025 |
4 | Acquisition by Rodney Williams of 100000 shares of Zomedica Pharmaceuticals at 0.069 subject to Rule 16b-3 | 03/21/2025 |
5 | Zomedica Corp. Announces Transition to OTCQB Venture Market - ACCESS Newswire | 04/25/2025 |
About Zomedica Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Zomedica or other delisted stocks. Alpha measures the amount that position in Zomedica Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Zomedica Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Zomedica Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Zomedica Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Zomedica Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Zomedica Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Zomedica Pharmaceuticals' management manipulating its earnings.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Zomedica Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Consideration for investing in Zomedica Stock
If you are still planning to invest in Zomedica Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Zomedica Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |